PH12014500352B1 - Site-directed modification of fviii - Google Patents

Site-directed modification of fviii

Info

Publication number
PH12014500352B1
PH12014500352B1 PH12014500352A PH12014500352A PH12014500352B1 PH 12014500352 B1 PH12014500352 B1 PH 12014500352B1 PH 12014500352 A PH12014500352 A PH 12014500352A PH 12014500352 A PH12014500352 A PH 12014500352A PH 12014500352 B1 PH12014500352 B1 PH 12014500352B1
Authority
PH
Philippines
Prior art keywords
site
fviii
directed modification
polyethylene glycol
factor viii
Prior art date
Application number
PH12014500352A
Other languages
English (en)
Other versions
PH12014500352A1 (en
Inventor
Clark Q Pan
John E Murphy
Baisong Mei
Jonathan S Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Liang Tang
Deqian Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014500352(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PH12014500352A1 publication Critical patent/PH12014500352A1/en
Publication of PH12014500352B1 publication Critical patent/PH12014500352B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
PH12014500352A 2004-11-12 2014-02-12 Site-directed modification of fviii PH12014500352B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (2)

Publication Number Publication Date
PH12014500352A1 PH12014500352A1 (en) 2015-07-20
PH12014500352B1 true PH12014500352B1 (en) 2019-09-25

Family

ID=36337298

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12014500352A PH12014500352B1 (en) 2004-11-12 2014-02-12 Site-directed modification of fviii
PH12019501613A PH12019501613A1 (en) 2004-11-12 2019-07-09 Site-directed modification of fviii

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12019501613A PH12019501613A1 (en) 2004-11-12 2019-07-09 Site-directed modification of fviii

Country Status (32)

Country Link
US (4) US7632921B2 (OSRAM)
EP (9) EP3323829B1 (OSRAM)
JP (5) JP2008524117A (OSRAM)
KR (7) KR101483917B1 (OSRAM)
CN (6) CN101124331B (OSRAM)
AU (1) AU2005304622B2 (OSRAM)
BE (1) BE2019C523I2 (OSRAM)
BR (2) BRPI0517795B8 (OSRAM)
CA (1) CA2586379C (OSRAM)
CY (3) CY1119292T1 (OSRAM)
DK (3) DK2363414T3 (OSRAM)
ES (4) ES2821832T3 (OSRAM)
FR (1) FR19C1031I2 (OSRAM)
HN (1) HN2007015683A (OSRAM)
HR (2) HRP20180481B1 (OSRAM)
HU (5) HUE033776T2 (OSRAM)
IL (3) IL182903A (OSRAM)
LT (5) LT3130601T (OSRAM)
LU (1) LUC00118I2 (OSRAM)
MA (1) MA29663B1 (OSRAM)
MX (3) MX2007005466A (OSRAM)
NL (1) NL300989I2 (OSRAM)
NO (3) NO20210454A1 (OSRAM)
NZ (1) NZ555032A (OSRAM)
PH (2) PH12014500352B1 (OSRAM)
PL (3) PL2363414T3 (OSRAM)
PT (4) PT2363414T (OSRAM)
RU (1) RU2423380C2 (OSRAM)
SI (4) SI3130601T1 (OSRAM)
UA (1) UA95225C2 (OSRAM)
WO (1) WO2006053299A2 (OSRAM)
ZA (1) ZA200703696B (OSRAM)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN104593348A (zh) * 2006-05-24 2015-05-06 诺沃—诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
EP2626079A3 (en) * 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
CA2724630A1 (en) 2008-05-16 2009-11-19 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
BRPI0920259A8 (pt) * 2008-10-17 2017-09-19 Baxter Healthcare Sa Molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea
US20120027743A1 (en) * 2008-11-03 2012-02-02 Bayer Healthcare Llc Method for the Treatment of Hemophilia
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US20110306551A1 (en) * 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
MX2011009803A (es) * 2009-03-20 2011-09-30 Hanmi Holdings Co Ltd Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico.
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
CN102573920B (zh) 2009-07-27 2015-01-14 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TWI537006B (zh) 2009-07-27 2016-06-11 巴克斯歐塔公司 凝血蛋白接合物
US9062299B2 (en) * 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
EA038618B1 (ru) 2009-12-06 2021-09-23 Биовератив Терапьютикс Инк. Химерные и гибридные полипептиды фактора viii-fc и способы их применения
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
CN106432557A (zh) 2010-04-15 2017-02-22 科迪亚科学企业公司 高分子量的含两性离子的聚合物
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
MX347503B (es) * 2010-11-05 2017-04-26 Baxalta Inc Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
EP3808378A1 (en) * 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
RS58578B1 (sr) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
RU2017101333A (ru) 2011-09-23 2018-12-19 Ново Нордиск А/С Новые аналоги глюкагона
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
SG10201606783RA (en) 2012-02-15 2016-10-28 Amunix Operating Inc Factor viii compositions and methods of making and using same
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
RS60003B1 (sr) 2013-03-15 2020-04-30 Bioverativ Therapeutics Inc Formulacije polipeptida faktora viii
KR20150132449A (ko) * 2013-03-15 2015-11-25 바이엘 헬스케어 엘엘씨 재조합 인자 viii 제제
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
PT3041513T (pt) 2013-09-08 2020-09-07 Kodiak Sciences Inc Conjugados de polímeros zwiteriónicos com fator viii
MX2016005333A (es) * 2013-10-22 2017-02-15 Dbv Tech Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos.
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
US10822393B2 (en) 2014-01-20 2020-11-03 Octapharma Ag Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
KR20230136616A (ko) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
CA2944909A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
EP3129463B1 (en) 2014-04-10 2021-05-26 Bayer Healthcare LLC Compounded media powder formulation and method of preparation of liquid medium for cell culture
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112017018468A2 (pt) 2015-03-06 2018-04-17 Csl Behring Recombinant Facility Ag fator de von willebrand modificado com meia-vida aumentada
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FACTOR IX FUSION PROTEINS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108779165B (zh) 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
ES2909573T3 (es) 2016-01-07 2022-05-09 CSL Behring Lengnau AG Factor de von Willebrand truncado mutado
WO2017222330A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
CN110381986B (zh) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
AU2017360979A1 (en) 2016-11-16 2019-05-30 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
MA46967A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
CR20190389A (es) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
US20220403005A1 (en) * 2019-12-06 2022-12-22 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
EP0776530A4 (en) * 1995-06-21 1998-06-10 Motorola Inc METHOD AND ANTENNA PRODUCING AN OMNIDIRECTIONAL RADIATION DIAGRAM
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
IL128229A0 (en) * 1996-08-02 1999-11-30 Ortho Mcneil Pharm Inc Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
BR9812267B1 (pt) 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO1999020288A1 (en) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
ES2233036T3 (es) 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
AU775529B2 (en) 1998-11-10 2004-08-05 Stichting Sanquin Bloedvoorziening A factor VIII-polypeptide with factor VIII:C-activity
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2359345A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000071714A2 (en) 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
CA2397347C (en) * 2000-02-11 2011-07-12 Maxygen Aps Factor vii or viia-like molecules
MXPA03002256A (es) 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
EP1351986A2 (en) 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2002077218A1 (en) * 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
ATE417618T1 (de) 2001-10-05 2009-01-15 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
EP1495052B9 (en) 2002-04-18 2009-12-16 MERCK PATENT GmbH Modified factor viii
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
US7329721B2 (en) 2002-12-31 2008-02-12 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
PT1596887T (pt) 2003-02-26 2022-04-14 Nektar Therapeutics Conjugados polímero-porção fator viii
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
MXPA05012315A (es) * 2003-05-12 2006-04-18 Affymax Inc Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos.
CA2510040C (en) 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1699469B1 (en) 2003-12-03 2010-04-07 University of Rochester Recombinant factor viii having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006103298A2 (en) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII

Also Published As

Publication number Publication date
ES2633916T3 (es) 2017-09-26
MX2007005466A (es) 2007-10-19
KR20140019489A (ko) 2014-02-14
EP3130601A1 (en) 2017-02-15
CY1119292T1 (el) 2018-02-14
PL2371856T3 (pl) 2022-08-22
BRPI0517795B1 (pt) 2020-03-31
US9364520B2 (en) 2016-06-14
BRPI0517795B8 (pt) 2021-05-25
HUE059193T2 (hu) 2022-10-28
DK1824988T3 (en) 2017-08-07
IL232540A (en) 2017-08-31
EP2363414A2 (en) 2011-09-07
PT2371856T (pt) 2022-08-12
SI1824988T1 (sl) 2017-11-30
US20060115876A1 (en) 2006-06-01
UA95225C2 (ru) 2011-07-25
EP2363414A3 (en) 2012-03-21
JP2015134780A (ja) 2015-07-27
MX392760B (es) 2025-03-24
EP2772500A1 (en) 2014-09-03
LT2371856T (lt) 2022-08-25
EP3243833A1 (en) 2017-11-15
HRP20070268A2 (hr) 2007-09-30
IL182903A0 (en) 2007-08-19
HK1182121A1 (en) 2013-11-22
EP3323829A1 (en) 2018-05-23
PL2363414T3 (pl) 2022-09-05
NL300989I1 (nl) 2019-05-22
JP2013067621A (ja) 2013-04-18
CA2586379C (en) 2012-04-03
LUC00118I2 (OSRAM) 2019-12-27
BRPI0517795A (pt) 2008-10-21
CN101124331A (zh) 2008-02-13
IL234433B (en) 2019-11-28
HUE033776T2 (en) 2018-01-29
EP3130601B1 (en) 2020-07-15
EP1824988A2 (en) 2007-08-29
US9096656B2 (en) 2015-08-04
HUS1900026I1 (hu) 2022-04-28
KR101243564B1 (ko) 2013-03-27
IL232540A0 (en) 2014-06-30
PL1824988T3 (pl) 2018-01-31
LTPA2019509I1 (lt) 2019-08-26
ZA200703696B (en) 2008-08-27
US20130274445A1 (en) 2013-10-17
BR122016022033B8 (pt) 2021-05-25
JP2008524117A (ja) 2008-07-10
LT2363414T (lt) 2022-10-25
JP6559642B2 (ja) 2019-08-14
ES2821832T3 (es) 2021-04-27
EP3243833B1 (en) 2020-06-17
LT3130601T (lt) 2020-09-10
DK2363414T3 (da) 2022-08-08
CY2019024I2 (el) 2019-11-27
CN107082806A (zh) 2017-08-22
CN103214569B (zh) 2016-12-28
PH12014500352A1 (en) 2015-07-20
KR101468345B1 (ko) 2014-12-03
MA29663B1 (fr) 2008-08-01
KR20160105928A (ko) 2016-09-07
KR20130036780A (ko) 2013-04-12
NO20072997L (no) 2007-06-27
MX350293B (es) 2017-09-04
CN103214569A (zh) 2013-07-24
HK1218718A1 (zh) 2017-03-10
KR101483917B1 (ko) 2015-01-16
KR20140091618A (ko) 2014-07-21
RU2423380C2 (ru) 2011-07-10
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
HK1117875A1 (en) 2009-01-23
CY1123384T1 (el) 2021-12-31
EP3153181A1 (en) 2017-04-12
DK2371856T3 (en) 2022-08-08
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
AU2005304622A1 (en) 2006-05-18
IL182903A (en) 2014-09-30
WO2006053299A2 (en) 2006-05-18
PT1824988T (pt) 2017-07-21
CN105148287A (zh) 2015-12-16
CN105148287B (zh) 2019-07-09
CN103102406A (zh) 2013-05-15
JP6487895B2 (ja) 2019-03-20
CN101124331B (zh) 2013-04-24
ES2930159T3 (es) 2022-12-07
PT2363414T (pt) 2022-08-04
EP3323829B1 (en) 2020-07-15
BR122016022033B1 (pt) 2021-03-02
HRP20180481B1 (hr) 2022-02-18
NL300989I2 (nl) 2019-11-28
LT1824988T (lt) 2017-10-25
KR20180110192A (ko) 2018-10-08
PT3130601T (pt) 2020-10-01
EP2371856B1 (en) 2022-05-18
EP1824988A4 (en) 2008-12-31
FR19C1031I1 (OSRAM) 2019-06-28
WO2006053299A3 (en) 2006-08-24
AU2005304622B2 (en) 2012-03-29
HRP20070268B1 (hr) 2018-04-20
EP2772500B1 (en) 2019-12-25
NO20200044A1 (no) 2007-06-27
KR101904630B1 (ko) 2018-10-04
JP6109523B2 (ja) 2017-04-05
HUE050542T2 (hu) 2020-12-28
CN105753968A (zh) 2016-07-13
HN2007015683A (es) 2011-07-11
JP2017101028A (ja) 2017-06-08
CN103102406B (zh) 2015-05-27
US7632921B2 (en) 2009-12-15
US20160051633A1 (en) 2016-02-25
PH12019501613A1 (en) 2020-09-14
EP3243834A1 (en) 2017-11-15
LTC1824988I2 (lt) 2021-02-25
FR19C1031I2 (fr) 2020-06-05
NO345800B1 (no) 2021-08-09
ES2930143T3 (es) 2022-12-07
NO344606B1 (no) 2020-02-10
BE2019C523I2 (OSRAM) 2025-02-10
HUE060016T2 (hu) 2023-01-28
EP2363414B1 (en) 2022-05-18
CY2019024I1 (el) 2019-11-27
SI3130601T1 (sl) 2020-11-30
KR20120136413A (ko) 2012-12-18
JP2017105773A (ja) 2017-06-15
US20100081615A1 (en) 2010-04-01
SI2371856T1 (sl) 2022-09-30
KR101654011B1 (ko) 2016-09-05
EP1824988B1 (en) 2017-04-19
LUC00118I1 (OSRAM) 2019-05-13
EP2371856A3 (en) 2012-03-14
BRPI0517795A8 (pt) 2018-12-26
RU2007121517A (ru) 2008-12-20
EP2371856A2 (en) 2011-10-05
NZ555032A (en) 2010-02-26
CA2586379A1 (en) 2006-05-18
HRP20180481A2 (hr) 2018-06-29

Similar Documents

Publication Publication Date Title
PH12019501613A1 (en) Site-directed modification of fviii
WO2006047419A3 (en) Heterobifunctional poly(ethylene glycol) and uses thereof
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
WO2005091944A3 (en) Glycol linked fgf-21 compounds
NO20031179L (no) Chemokin-reseptorbindende heterocykliske forbindelser
TR200400295T2 (tr) Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi
WO2006103298A3 (en) Blood coagulation fviii analogues
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
GEP20074016B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1663171A4 (en) HETEROFUNCTIONAL COPOLYMERS OF GLYCEROL AND POLYETHYLENE GLYCOL, CONJUGATES AND COMPOSITIONS THEREOF
CY1116415T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν l-733060 για χρηση στη θεραπευτικη αγωγη καρκινικων ογκων
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
WO2005084303A3 (en) Interferon-beta polymer conjugates
MY151329A (en) Site-directed modification of fviii
MY181129A (en) Site-directed modification of fviii
MY173864A (en) Site-directed modification of fviii
DE60313786D1 (de) Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
CY1125477T1 (el) Κατευθυνομενη απο θεση τροποποιηση του fviii
SV2007002756A (es) Modificacion dirigida al sitio del fviii
UA90805C2 (en) Polyethylene glycol-interferon alpha conjugate
PL1668027T3 (pl) Cykliczne peptydy działające jako antagoniści Urotensyny-II